查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840788

合成生物學市場（按產品、技術、應用和最終用戶分類）—2025-2032 年全球預測

Synthetic Biology Market by Product, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年合成生物市場規模將成長至 481.8 億美元，複合年成長率為 17.04%。

主要市場統計數據
基準年2024年 136.7億美元
預計2025年 158億美元
預測年份：2032年 481.8億美元
複合年成長率（%） 17.04%

簡潔而策略性地說明合成生物學的跨學科創新及其對商業和科學領導者的戰略意義

本執行摘要介紹了合成生物學這個跨學科領域，它正在重塑生物系統的設計、工程和商業化規模化。引言將合成生物學置於運算設計、精密工程和濕實驗室創新融合的時代背景下，為農業、工業製造、環境應用和生命科學領域帶來新的產品和服務。透過探討技術力和市場動態，本文強調了決策者應優先關注和投資的領域。

本章闡述了合成生物學為企業帶來的核心價值：透過自動化模組化設計加速產品開發週期，透過標準化生物組件來提高可重複性，以及隨著合成生物學取代傳統化學和農業流程而帶來的下游成本優勢。本章也重點介紹了軟體開發商、設備製造商和服務供應商如何夥伴關係，打造一個能夠實現先進生物工程商業性化的生態系統。引言部分概述了後續分析的結構，並重點介紹了後續章節，這些章節探討了變革性轉變、政策影響、細分考慮、區域動態、競爭定位、領導者建議、研究方法以及支持戰略決策的結論和背景。

自動化、競爭性設計和先進基因組學的快速整合如何重塑競爭優勢並加速跨產業的產品創新

合成生物學正在經歷變革性的轉變，這種轉變超越了漸進式的技術改進，並從根本上改變了產品的構思、設計和交付方式。其中最重要的轉變之一是計算設計工具與實驗室自動化的日益整合，將「設計-建造-測試-學習」的週期從數月縮短至數週。這種融合使團隊能夠快速迭代基因構建體、代謝途徑和合成底盤，從而催生新的產品類別。

同時，從DNA合成儀、新一代定序儀到可程式生物反應器等模組化硬體平台的日趨成熟，催生了標準化介面，加速了不同供應商和實驗室之間的互通性。隨著儀器越來越普及，軟體也越來越複雜，分散式研究模式正在興起，分散的團隊在共用設計庫和遠端執行平台上進行協作。這種去中心化模式也改變了人才格局，推動了對能夠連接計算和生物學專業知識的專家以及能夠提供端到端計劃執行的服務供應商的需求。

另一個變革軸心是先進基因組編輯和合成基因組學技術的興起，它們擴大了可能的生物功能範圍。 CRISPR 衍生工具以及高通量基因合成和自動化組裝方法的廣泛應用，使得諸如路徑最佳化和底盤最小化等複雜的工程任務能夠以以前無法實現的規模完成。這些技術變革與不斷變化的監管互動和日益嚴格的公眾監督同步發生，迫使組織採用更強力的管治框架和透明的傳播策略。總之，這些變化正在重塑競爭優勢，有利於那些能夠結合平台規模研發、多學科人才和嚴格管治來建立可重複產品開發流程的公司。

評估近期關稅變化如何重塑採購、製造和籌資策略

美國近期的貿易政策變化和關稅調整，為依賴跨境供應鏈採購儀器、耗材和專用試劑的公司帶來了新的成本考量。關稅的累積影響在整個價值鏈上呈現不均衡的態勢，而定序儀和合成器等資本設備的進口關稅高於模組化軟體和本地服務。這種不對稱獎勵企業重新評估籌資策略，加快某些製造流程的在地化，並在受影響較小的地區尋找替代供應商。

為了應對這項挑戰，採購團隊和研發負責人正在採取一系列短期和中期策略。短期因應措施包括重新協商供應合約、增加關鍵任務耗材的安全庫存，以及利用合約研究機構來彌補產能限制。中期而言，企業正在考慮投資區域高價值零件製造中心，並建立夥伴關係，將知識轉移給本地製造合作夥伴。決策者正在權衡確保供應鏈韌性的需求與從創新專案轉移資金的機會成本。

同時，關稅主導的成本壓力正推動儀器製造商和試劑供應商加強合作，以打造價格和交付更可預測的捆綁解決方案。這種商業性結構降低了交易複雜性，並幫助最終用戶管理整體擁有成本。政策波動也凸顯了情境規劃和壓力測試採購模型的重要性。那些擁有多元化採購管道、建立關鍵物資策略儲備並積極與政策顧問溝通的機構，將更有能力保持研究的連續性並減輕商業性中斷的影響。

多方面的細分分析揭示了產品、技術、應用和最終用戶向量如何融合以形成採用路徑和商業化策略

深入的細分能夠揭示價值創造的領域、能力的聚集方式以及商業化的路徑。在耗材和試劑領域，酵素和蛋白質、套件和試劑盒、培養基和補充劑代表不同的購買行為和生命週期需求；而設備則包括生物資訊工作站、PCR儀、定序儀和合成儀，用於支援實驗室產能和資本規劃。此產品視角闡明了一次性資本支出和經常性試劑成本在採購週期上的差異，為策略夥伴關係關係和定價模型提供參考。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 利用基於 CRISPR 的基因迴路開發針對固態腫瘤的可程式設計細胞療法
  • 擴大微生物發酵規模，實現高價值生物基化學品的工業規模永續生產
  • 整合人工智慧驅動設計與機器學習，加速微生物生物合成途徑最佳化
  • 採用無細胞平台進行快速原型製作和按需生物製造治療劑
  • 模組化蛋白質支架在代謝工程中用於精確酵素共定位的進展
  • 合成生物產品監管環境的不斷變化將加快主要市場的核准
  • 生物防護策略投資激增，以解決基因改造生物在環境中釋放的安全問題
  • 改善質地並提高成本競爭力的合成生物培養肉產品的商業化
  • 開發整合機器人技術和高通量分析的晶圓代工廠，實現自動化應變工程工作流程
  • 合成最小細胞作為客製化生物感測和環境修復的多功能底盤的出現

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章合成生物學市場：依產品

  • 耗材和試劑
    • 酵素和蛋白質
    • 套件和檢測試劑
    • 媒體和補充資料
  • 裝置
    • 生物資訊工作站
    • PCR儀
    • 序列器
    • 合成器
  • 服務
  • 軟體

第9章合成生物學市場：依技術

  • 生物資訊學工具
    • 資料管理
    • 設計自動化
    • 序列分析
  • 細胞工程
    • 細胞株開發
    • 合成細胞設計
  • 基因合成
    • DNA列印
    • 基因組組裝
    • 寡核苷酸合成
  • 基因組編輯
    • CRISPR Cas
    • Meganucleases
  • 合成基因組學
    • 最小細胞
    • 外來生物學

第 10 章合成生物學市場：按應用

  • 農業
    • 基因改造作物
    • 合成肥料
  • 環境
    • 生物修復
    • 碳捕獲
    • 廢棄物處理
  • 產業
    • 生物催化劑
    • 生質燃料
    • 生質塑膠和生物聚合物
    • 特種化學品
  • 生命科學
    • 藥物研發
    • 基因治療
    • 個人化醫療
    • 疫苗研發

第 11 章。合成生物學市場（按最終用戶）

  • 學術研究機構
  • 農業和食品公司
  • 合約研究組織
  • 製藥和生物技術公司

第 12 章。按地區分類的合成生物學市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章合成生物學市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。按國家/地區分類的合成生物學市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Agilent Technologies, Inc.
    • Illumina, Inc.
    • Amyris, Inc.
    • Arzeda
    • Batavia Biosciences BV
    • Beam Therapeutics
    • Beckman Coulter, Inc. by Danaher Corporation
    • BGI Genomics Co., Ltd.
    • Codexis, Inc.
    • Conagen, Inc.
    • Creative Enzymes
    • DNA TwoPointO Inc.
    • Editas Medicine, Inc.
    • Eurofins Scientific SE
    • GenScript Biotech Corporation
    • Ginkgo Bioworks, Inc.
    • Integrated DNA Technologies, Inc.
    • Merck KGaA
    • New England Biolabs GmbH
    • Novozymes A/S
    • Precigen, Inc.
    • QIAGEN NV
    • Sangamo Therapeutics
    • Scarab Genomics, LLC
    • Synlogic
    • Synthego Corporation
    • TeselaGen Service
    • Thermo Fisher Scientific Inc.
    • Twist Bioscience Corporation
Product Code: MRR-B9334AD6BE33

The Synthetic Biology Market is projected to grow by USD 48.18 billion at a CAGR of 17.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.67 billion
Estimated Year [2025] USD 15.80 billion
Forecast Year [2032] USD 48.18 billion
CAGR (%) 17.04%

A concise and strategic orientation that frames synthetic biology's multidisciplinary innovations and their strategic implications for commercial and scientific leaders

This executive summary introduces synthetic biology as a fundamentally interdisciplinary field that is reshaping how biological systems are designed, engineered, and scaled for commercial use. The introduction situates synthetic biology within a landscape where computational design, precision engineering, and wet-lab innovation converge to enable new classes of products and services across agriculture, industrial manufacturing, environmental applications, and life sciences. By framing the discussion around both technological capability and market adoption dynamics, the narrative emphasizes where decision-makers should prioritize attention and investment.

The section proceeds by articulating the core value propositions that synthetic biology unlocks for organizations: accelerated product development cycles through modular design automation, enhanced reproducibility via standardized biological parts, and downstream cost advantages where engineered biology displaces traditional chemical or agricultural processes. It further highlights how partnerships between software developers, instrument manufacturers, and service providers form the ecosystem that makes advanced biological engineering commercially tractable. The introduction closes by outlining the structure of the analysis to follow, clarifying that subsequent sections will examine transformative shifts, policy impacts, segmentation insights, regional dynamics, competitive positioning, recommendations for leaders, research methods, and conclusive context to support strategic decisions.

How rapid integration of automation, computational design, and advanced genomics is rewriting competitive advantage and accelerating product innovation across sectors

Synthetic biology is experiencing transformative shifts that extend beyond incremental technological improvements to fundamental changes in how products are conceived, designed, and delivered. One of the most consequential shifts is the increasing integration of computational design tools with lab automation, enabling design-build-test-learn cycles to compress from months to weeks. This convergence is unlocking new product classes by allowing teams to iterate rapidly on genetic constructs, metabolic pathways, and synthetic chassis, while also reducing the barriers to entry for organizations without deep wet-lab heritage.

Concurrently, the maturation of modular hardware platforms-ranging from DNA synthesizers and next-generation sequencers to programmable bioreactors-has created standardized interfaces that accelerate interoperability across vendors and labs. As instruments become more accessible and software becomes more sophisticated, a decentralized research model is emerging in which distributed teams can collaborate on shared design repositories and remote execution platforms. This distribution is altering talent dynamics, with demand shifting toward professionals who bridge computational and biological expertise and toward service providers who can deliver end-to-end project execution.

Another axis of transformation is the rise of advanced genome editing and synthetic genomics techniques, which broaden the palette of achievable biological functions. The diffusion of CRISPR-derived tools alongside high-throughput gene synthesis and automated assembly methods is enabling complex engineering tasks such as pathway optimization and chassis minimization at scales that were previously impractical. These technological shifts are paralleled by evolving regulatory conversations and increasing public scrutiny, prompting organizations to adopt more robust governance frameworks and transparent communication strategies. Taken together, these transformations are reshaping competitive advantage to favor entities that can combine platform-scale R&D, cross-disciplinary talent, and disciplined governance into repeatable product development processes.

Assessing how recent tariff shifts have reconfigured sourcing, manufacturing, and procurement strategies with tangible implications for resilience and product delivery timelines

Recent trade policy developments and tariff adjustments in the United States have introduced new cost considerations for companies that rely on cross-border supply chains for instruments, consumables, and specialized reagents. The cumulative impact of tariffs has been felt unevenly across the value chain, with capital equipment such as sequencers and synthesizers bearing higher exposure to import duties relative to modular software and local services. This asymmetry has created incentives for organizations to reassess sourcing strategies, accelerate localization of certain manufacturing processes, and explore alternative suppliers in less affected jurisdictions.

In response, procurement teams and R&D leaders have adopted a mix of short- and medium-term tactics. Short-term responses include renegotiating supply contracts, increasing safety stock of mission-critical consumables, and leveraging contract research organizations to bridge capacity constraints. Over the medium term, companies are contemplating investments in regionalized manufacturing hubs for high-value components and building partnerships that transfer knowledge to local production partners. These shifts are changing the calculus for capital allocation: decision-makers are balancing the need to secure resilient supply chains against the opportunity costs of diverting funds from innovation programs.

At the same time, tariff-driven cost pressures have heightened collaboration between instrument manufacturers and reagent suppliers to create bundled solutions that can be priced and shipped more predictably. Such commercial constructs reduce transactional complexity and help end users manage total cost of ownership. Policy volatility has also elevated the importance of scenario planning and stress-testing of procurement models. Organizations that maintain diversified sourcing, cultivate strategic stockpiles for critical items, and engage proactively with policy advisors will be better positioned to sustain research continuity and mitigate commercial disruption.

Multidimensional segmentation analysis revealing how product, technology, application, and end-user vectors converge to shape adoption pathways and commercialization strategies

Insightful segmentation reveals where value is created, how capabilities cluster, and which pathways lead to commercialization. Based on product, the market spans consumables and reagents, instruments, services, and software; within consumables and reagents, enzymes and proteins, kits and assays, and media and supplements represent distinct purchasing behaviors and lifecycle needs, while instruments encompass bioinformatics workstations, PCR machines, sequencers, and synthesizers that anchor lab capabilities and capital planning. This product lens clarifies how purchasing cycles differ between one-time capital investments and recurring reagent spend, informing strategic partnerships and pricing models.

Based on technology, the landscape is organized around bioinformatics tools, cell engineering, gene synthesis, genome editing, and synthetic genomics; bioinformatics tools further decompose into data management, design automation, and sequence analysis, whereas cell engineering splits into cell line development and synthetic cell design. Gene synthesis breaks down into DNA printing, gene assembly, and oligonucleotide synthesis, while genome editing separates into CRISPR Cas technologies and meganucleases; synthetic genomics includes approaches such as minimal cell design and xenobiology. This technology-based segmentation highlights where R&D investments concentrate and which platform capabilities will be foundational for next-generation products.

Based on application, the field extends across agriculture, environmental, industrial, and life sciences; within agriculture, genetically modified crops and synthetic fertilizers point to agronomic productivity and input optimization, while environmental use cases-bioremediation, carbon capture, and waste treatment-underscore sustainability-focused deployments. Industrial applications include biocatalysts, biofuels, bioplastics and biopolymers, and specialty chemicals, each with distinct scale-up and regulatory paths, and life sciences applications encompass drug discovery, gene therapy, personalized medicine, and vaccine development, where clinical validation and regulatory clearance shape timelines. Finally, based on end user, the market is organized around academic and research institutes, agriculture and food companies, contract research organizations, and pharmaceutical and biotechnology companies, each with unique procurement governance, adoption velocity, and partnership models. Together, these segmentation perspectives form a multidimensional map that leaders can use to align product roadmaps, go-to-market strategies, and partnership priorities with distinct user needs and technology maturities.

Comparative regional dynamics and strategic implications illustrating how regulatory regimes, manufacturing capacity, and funding ecosystems influence adoption across global markets

Regional dynamics materially influence how technologies are adopted, regulated, and commercialized, and a comparative view across the Americas, Europe Middle East and Africa, and Asia-Pacific highlights differentiated priorities and strengths. In the Americas, innovation ecosystems anchored by strong venture capital networks and advanced research institutions tend to accelerate translational activity and early-stage commercialization, with particular strength in life sciences applications and synthetic biology platforms that support therapeutics and diagnostics. This region's regulatory environment and proximity to large biotech clusters also support rapid iterations between research and market-entry activities.

Across Europe, Middle East and Africa, policy frameworks and public funding instruments emphasize biosecurity, ethical governance, and sustainability, which influence the development of environmental and industrial applications. Collaboration between national research centers and industry consortia is common, and regulatory stringency often shapes product design choices, particularly for agricultural and environmental deployments. In the Asia-Pacific region, manufacturing scale, cost-competitive production capacity, and rapidly growing domestic markets create opportunities for scaling upstream production of reagents and instruments as well as for industrial biotech applications such as bioplastics, specialty chemicals, and biofuels. Local regulatory regimes and national industrial strategies in this region can accelerate adoption where alignment exists between government priorities and private-sector investment. Recognizing these regional differentials enables more effective market entry sequencing, supply chain decisions, and talent recruitment strategies that reflect local strengths and constraints.

Competitive landscape insights highlighting why platform integration, specialist innovation, and strategic partnerships determine who scales successfully in synthetic biology markets

Competitive positioning within synthetic biology is shaped by companies that combine platform technologies, deep application expertise, and integrated service offerings. Leading firms prioritize vertical integration across design tools, instruments, and services to capture more of the value chain and to reduce friction for end users. These integrated players often invest heavily in proprietary data assets and workflow automation, enabling them to shorten development cycles and to offer higher levels of reproducibility and scalability than more narrowly focused rivals.

At the same time, specialist companies that focus on a single segment-such as high-precision DNA synthesis, novel enzyme production, or design automation software-retain strategic importance because they drive technical innovation and create partnership opportunities for platform providers. Contract research organizations and service providers play a critical role in de-risking early-stage projects and in enabling companies without large internal labs to access advanced capabilities. Partnerships between instrument manufacturers and reagent suppliers are increasingly common as a means to create turnkey solutions that reduce adoption friction for end users.

Investor attention and strategic partnerships are frequently directed toward firms that demonstrate clear pathways to regulatory readiness, strong intellectual property positions, and defensible data moats. Organizations that can articulate robust safety and governance models alongside compelling technical performance are better positioned to win public trust and to accelerate commercialization. Ultimately, competitive differentiation increasingly depends on the ability to translate technical capability into repeatable commercial processes that customers can deploy reliably at scale.

Actionable strategic priorities for leaders to align infrastructure, governance, talent, and partnerships to accelerate commercialization while managing regulatory and supply risks

Industry leaders should prioritize a set of actionable measures that align technological capability with commercial imperatives and regulatory realities. First, invest in modular infrastructure that supports rapid iteration: adopt interoperable instruments, standardize data formats, and implement laboratory automation to compress development timelines and reduce error rates. These investments not only speed innovation but also create operational leverage as product portfolios expand. Second, develop supply chain resilience by diversifying supplier relationships, evaluating regional production partnerships, and negotiating flexible contracts to mitigate tariff and logistics volatility. Proactive procurement planning reduces downtime and preserves R&D momentum.

Third, adopt robust governance and stakeholder engagement strategies that transparently address biosafety, biosecurity, and ethical considerations. Clear communication and third-party validation of safety frameworks will be essential for building public trust and for smoothing regulatory interactions. Fourth, cultivate cross-disciplinary talent by investing in training programs that bridge computational, molecular, and engineering skill sets; fostering internal centers of excellence will accelerate the integration of design automation and lab execution. Fifth, pursue targeted partnerships and platform bundling with complementary vendors to deliver turnkey solutions for customers, thereby lowering adoption barriers and creating recurring revenue opportunities. Finally, embed scenario planning and stress-testing into strategic processes to prepare for policy shifts, supply disruptions, and rapid technology changes. Leaders who combine operational resilience, ethical governance, and focused commercialization pathways will capture the most enduring advantages.

A transparent, mixed-methods research approach combining interviews, technical literature, and scenario analysis to produce actionable and validated insights for decision-makers

The research underpinning this summary employed a mixed-methods approach designed to triangulate qualitative insight with quantitative validation, emphasizing reproducibility and transparency. Primary research included structured interviews with executives, R&D leaders, and procurement specialists across instrument manufacturers, reagent suppliers, service providers, and end-user organizations. These conversations provided context on adoption drivers, procurement cycles, and the commercial implications of recent policy shifts. Secondary research incorporated peer-reviewed scientific literature, regulatory guidance, and technical white papers to ground technological descriptions and to ensure accuracy in portraying method capabilities and limitations.

Analytical methods combined thematic analysis of interview data with comparative technology mapping to identify capability clusters and adoption pathways. Supply chain and tariff impact assessments were informed by scenario analysis and procurement case studies that illustrate potential operational responses without relying on a single forecast. Throughout, quality controls included cross-validation of claims against multiple independent sources and review cycles with subject-matter experts to ensure factual accuracy and to correct technical nuance. The methodology focused on delivering insight that is both actionable and defensible, enabling leaders to make informed decisions about investment, partnerships, and operational resilience.

A conclusive synthesis underscoring the critical need to combine platform capability, resilient operations, and ethical governance to translate scientific potential into enduring commercial value

In conclusion, synthetic biology stands at an inflection point where technological convergence, evolving policy environments, and shifting commercial models create both significant opportunity and distinct risk. Organizations that adopt modular automation, cultivate interoperable software and data practices, and develop resilient supply chains will be better positioned to translate scientific innovation into sustainable commercial outcomes. Moreover, those that proactively address governance, ethical concerns, and public transparency will reduce friction in regulatory pathways and strengthen stakeholder trust.

The cumulative effect of these dynamics is a marketplace where competitive advantage accrues to entities that can coordinate platform capabilities, talent, and go-to-market execution while remaining adaptable to policy and supply-chain variability. Strategic clarity-rooted in rigorous segmentation, regional awareness, and a commitment to operational excellence-will separate leaders from followers. For any organization engaging with synthetic biology, the imperative is to act deliberately: align internal capabilities with external partnerships, stress-test assumptions under multiple scenarios, and embed ethical governance as a core business practice to sustain long-term value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Development of programmable cell therapies leveraging CRISPR-based gene circuits to target solid tumors
  • 5.2. Scaling up microbial fermentation for sustainable production of high-value bio-based chemicals at industrial scale
  • 5.3. Integration of AI-driven design and machine learning for accelerated biosynthetic pathway optimization in microbes
  • 5.4. Adoption of cell-free synthetic biology platforms for rapid prototyping and on-demand biomanufacturing of therapeutics
  • 5.5. Advancements in modular protein scaffolding for precise enzyme colocalization in metabolic engineering
  • 5.6. Regulatory landscape evolution for synthetic biology products enabling faster approvals across major markets
  • 5.7. Investment surge in biocontainment strategies to address safety concerns for environmental release of engineered organisms
  • 5.8. Commercialization of synthetic biology derived cultured meat products with improved texture and cost competitiveness
  • 5.9. Development of biofoundries integrating robotics and high throughput analytics for automated strain engineering workflows
  • 5.10. Emergence of synthetic minimal cells as versatile chassis for custom biosensing and environmental remediation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Synthetic Biology Market, by Product

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes & Proteins
    • 8.1.2. Kits & Assays
    • 8.1.3. Media & Supplements
  • 8.2. Instruments
    • 8.2.1. Bioinformatics Workstations
    • 8.2.2. PCR Machines
    • 8.2.3. Sequencers
    • 8.2.4. Synthesizers
  • 8.3. Services
  • 8.4. Software

9. Synthetic Biology Market, by Technology

  • 9.1. Bioinformatics Tools
    • 9.1.1. Data Management
    • 9.1.2. Design Automation
    • 9.1.3. Sequence Analysis
  • 9.2. Cell Engineering
    • 9.2.1. Cell Line Development
    • 9.2.2. Synthetic Cell Design
  • 9.3. Gene Synthesis
    • 9.3.1. DNA Printing
    • 9.3.2. Gene Assembly
    • 9.3.3. Oligonucleotide Synthesis
  • 9.4. Genome Editing
    • 9.4.1. CRISPR Cas
    • 9.4.2. Meganucleases
  • 9.5. Synthetic Genomics
    • 9.5.1. Minimal Cell
    • 9.5.2. Xenobiology

10. Synthetic Biology Market, by Application

  • 10.1. Agriculture
    • 10.1.1. Genetically Modified Crops
    • 10.1.2. Synthetic Fertilizers
  • 10.2. Environmental
    • 10.2.1. Bioremediation
    • 10.2.2. Carbon Capture
    • 10.2.3. Waste Treatment
  • 10.3. Industrial
    • 10.3.1. Biocatalysts
    • 10.3.2. Biofuels
    • 10.3.3. Bioplastics & Biopolymers
    • 10.3.4. Specialty Chemicals
  • 10.4. Life Sciences
    • 10.4.1. Drug Discovery
    • 10.4.2. Gene Therapy
    • 10.4.3. Personalized Medicine
    • 10.4.4. Vaccine Development

11. Synthetic Biology Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Agriculture & Food Companies
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Synthetic Biology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Synthetic Biology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Synthetic Biology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Agilent Technologies, Inc.
    • 15.3.2. Illumina, Inc.
    • 15.3.3. Amyris, Inc.
    • 15.3.4. Arzeda
    • 15.3.5. Batavia Biosciences B.V.
    • 15.3.6. Beam Therapeutics
    • 15.3.7. Beckman Coulter, Inc. by Danaher Corporation
    • 15.3.8. BGI Genomics Co., Ltd.
    • 15.3.9. Codexis, Inc.
    • 15.3.10. Conagen, Inc.
    • 15.3.11. Creative Enzymes
    • 15.3.12. DNA TwoPointO Inc.
    • 15.3.13. Editas Medicine, Inc.
    • 15.3.14. Eurofins Scientific SE
    • 15.3.15. GenScript Biotech Corporation
    • 15.3.16. Ginkgo Bioworks, Inc.
    • 15.3.17. Integrated DNA Technologies, Inc.
    • 15.3.18. Merck KGaA
    • 15.3.19. New England Biolabs GmbH
    • 15.3.20. Novozymes A/S
    • 15.3.21. Precigen, Inc.
    • 15.3.22. QIAGEN N.V.
    • 15.3.23. Sangamo Therapeutics
    • 15.3.24. Scarab Genomics, LLC
    • 15.3.25. Synlogic
    • 15.3.26. Synthego Corporation
    • 15.3.27. TeselaGen Service
    • 15.3.28. Thermo Fisher Scientific Inc.
    • 15.3.29. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS SYNTHETIC BIOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. SYNTHETIC BIOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. SYNTHETIC BIOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SYNTHETIC BIOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENZYMES & PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS WORKSTATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHESIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOINFORMATICS TOOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DESIGN AUTOMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SEQUENCE ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC CELL DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DNA PRINTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE ASSEMBLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY OLIGONUCLEOTIDE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENOME EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CRISPR CAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MEGANUCLEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY MINIMAL CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY XENOBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENETICALLY MODIFIED CROPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SYNTHETIC FERTILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ENVIRONMENTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOREMEDIATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CARBON CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY WASTE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOCATALYSTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY BIOPLASTICS & BIOPOLYMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY SPECIALTY CHEMICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY LIFE SCIENCES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY AGRICULTURE & FOOD COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL SYNTHETIC BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 319. G